Qiheng Wan

Dr. Qiheng Wan

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
JWJing Wang
Jing Wang
QWQiheng Wan
Qiheng Wan
ZHZehan Huang
Zehan Huang
HYHUANG Yu-qing
HUANG Yu-qing
BZBin Zhang
Bin Zhang
SWSong Wen
Song Wen
Background: Lipoprotein(a) [Lp(a)] is a genetically determined, atherogenic, and prothrombotic lipoprotein. However, its prognostic value in patients who undergo successful chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains undefined. Methods: This single-center retrospective cohort study included 1509 patients who underwent successful CTO PCI. The primary outcome was cardiovascular death; secondary outcome was major adverse cardiovascular events (MACEs, cardiovascular death or nonfatal myocardial infarction). Multivariable Cox regression and restricted cubic splines (RCS) assessed the association between Lp(a) and outcomes. Results: Over median follow-up of 810 days, 53 (3.5%) cardiovascular deaths and 62 (4.1%) MACEs occurred. Each 1-SD increase in log-transformed Lp(a) was associated with a 51% higher risk of cardiovascular death (aHR 1.51, 95% CI 1.11–2.05, p = 0.008) and a 44% higher risk of MACEs (aHR 1.44, 95% CI 1.09–1.91, p = 0.011). Compared with Lp(a) < 30 mg/dL, Lp(a) ≥ 50 mg/dL conferred a 2.07-fold higher risk of cardiovascular death (95% CI 1.07–4.00, p = 0.029) and a 1.94-fold higher risk of MACEs (95% CI 1.07–3.53, p = 0.030). RCS analysis demonstrated a linear dose–response relationship between log-transformed Lp(a) and both cardiovascular death (p for nonlinearity = 0.653) and MACEs (p for nonlinearity = 0.562). The association was modified by age, hypertension, and left ventricular ejection fraction and remained robust in sensitivity analyses. Conclusions: In patients undergoing successful CTO PCI, elevated Lp(a) was independently and linearly associated with higher risks of cardiovascular death and MACEs. These findings suggest that Lp(a) may serve as a useful prognostic marker to enhance risk stratification in this high-risk population. Large-scale prospective cohorts are needed to validate these findings before clinical translation can be considered.

Verified
Journal Article
Open access
PDF file
QWQiheng Wan
Qiheng Wan
SWSong Wen
Song Wen
JXJiquan Xiao
Jiquan Xiao
FHFeihuang Han
Feihuang Han
ZHZehan Huang
Zehan Huang
BZBin Zhang
Bin Zhang
Introduction: The uric acid-to-albumin ratio (UAR) is a novel cardiovascular biomarker, but its prognostic value in patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) remains unknown. Materials and Methods: This retrospective study enrolled 1513 consecutive patients who underwent successful CTO-PCI at a single center from February 2011 to December 2023. Patients were stratified by baseline UAR tertiles. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), and the secondary endpoint was all-cause mortality. Multivariable Cox regression and restricted cubic spline (RCS) analyses were performed. Results: During a median follow-up of 810 days, patients in the highest UAR tertile had significantly higher rates of MACCE (18.5%, 10.1%, and 7.5% across tertiles; p < 0.001) and all-cause mortality (10.7%, 3.8%, and 2.0%; p < 0.001). After multivariable adjustment, each one-unit increase in UAR was associated with a 6% higher risk of MACCE (HR 1.06; 95% CI 1.02–1.10; p = 0.002) and a 9% higher risk of all-cause mortality (HR 1.09; 95% CI 1.04–1.14; p < 0.001). Patients in the highest UAR tertile had significantly increased risks of MACCE (HR 1.90; 95% CI 1.25–2.90; p = 0.003) and all-cause mortality (HR 3.40; 95% CI 1.62–7.12; p = 0.001) compared with those in the lowest UAR tertile. RCS analysis showed significant overall associations between UAR and both MACCE and all-cause mortality, with no significant evidence of nonlinearity. Conclusions: Elevated baseline UAR was independently associated with long-term MACCE and all-cause mortality after successful CTO-PCI. These findings support UAR as a readily available prognostic marker but do not establish causality or support UAR-guided therapeutic decision-making. Prospective studies are needed for validation.

Verified
Journal Article
Open access
PDF file
JXJiquan Xiao
Jiquan Xiao
SWSong Wen
Song Wen
RXRenshang Xu
Renshang Xu
QWQiheng Wan
Qiheng Wan
XHXiang He
Xiang He
HYHuimin Yu
Huimin Yu
Background: This study aimed to investigate the association between the prognostic nutritional index (PNI) and long-term all-cause mortality and major adverse cardiovascular events (MACEs) in elderly patients with chronic total occlusion (CTO) after successful percutaneous coronary intervention (PCI). Methods: This retrospective study enrolled 745 consecutive patients aged ≥ 60 years with successfully revascularized CTO between February 2011 and April 2023. All-cause mortality was the primary endpoint. MACE, defined as the first occurrence of all-cause mortality, non-fatal myocardial infarction, stroke, or target-vessel revascularization (TVR), was the secondary endpoint. Cox proportional hazards models and restricted cubic spline (RCS) analyses were used to evaluate associations. Results: During a median follow-up of 813 days, 58 (7.8%) all-cause mortality and 101 (13.6%) MACE occurred. In the primary multivariable model (Model 2), each 1-unit increase in PNI was associated with a 15% reduced risk of all-cause mortality (HR 0.85, 95% CI 0.81–0.90; p < 0.001) and an 8% reduced risk of MACE (HR 0.92, 95% CI 0.88–0.96; p < 0.001). Compared with the T1 group, patients in the T2 group had a significantly lower risk of all-cause mortality (HR = 0.21, 95% CI: 0.10–0.44; p < 0.001) and MACE (HR = 0.38, 95% CI: 0.23–0.63; p = 0.002). Similarly, the T3 group showed a significantly lower risk of all-cause mortality (HR = 0.24, 95% CI: 0.11–0.52; p = 0.003) and MACE (HR = 0.49, 95% CI: 0.30–0.82; p = 0.007). These associations remained directionally consistent in exploratory models with more extensive covariate adjustment. RCS indicated a linear association between PNI and all-cause mortality (p = 0.959) and a nonlinear association with MACE (p = 0.017). Conclusion: In this single-center retrospective cohort of elderly patients after successful CTO-PCI, lower baseline PNI was associated with higher risks of all-cause mortality and MACE. PNI may be a useful risk stratification tool, but its clinical utility requires confirmation in prospective, externally validated studies before implementation.

Verified
Journal Article
Open access
PDF file
XHXingjie Huang
Xingjie Huang
DHDan Hu
Dan Hu
QWQiheng Wan
Qiheng Wan
HYHUANG Yu-qing
HUANG Yu-qing
DMDunliang Ma
Dunliang Ma
SWSong Wen
Song Wen
Background: Septal collateral channels (CCs) are generally preferred for retrograde chronic total occlusion (CTO) percutaneous coronary intervention (PCI) because epicardial CC injury may result in hemopericardium and cardiac tamponade. However, comparative evidence on the procedural safety and long-term clinical outcomes of epicardial versus septal CC use remains limited. Methods: We retrospectively analyzed 750 patients who underwent elective retrograde CTO PCI from January 2011 through April 2023. The primary procedural safety outcome was periprocedural pericardial effusion. The primary long-term outcome was major adverse cardiovascular events (MACEs), defined as all-cause death, nonfatal myocardial infarction, stroke, or unplanned revascularization. Multivariable logistic and Cox regression models were used to evaluate these outcomes. Results: 544 patients underwent retrograde CTO PCI through a septal CC and 206 through an epicardial CC. Pericardial effusion (7.3% vs. 1.7%; p < 0.001) and pericardiocentesis (5.3% vs. 1.1%; p = 0.001) were more frequent with epicardial CC use. CC wire crossing success (90.8% vs. 94.5%; p = 0.067), retrograde technical success (87.9% vs. 90.1%; p = 0.40), and overall recanalization success (90.3% vs. 91.0%; p = 0.80) did not differ significantly. Epicardial CC use was associated with higher odds of pericardial effusion (OR 5.60, 95% CI 2.26–14.70, p < 0.001). During a median follow-up of 1039 days, MACE occurred in 15.0% and 16.5% of the epicardial and septal CC groups, respectively (HR 1.10, 95% CI 0.71–1.70, p = 0.659). Conclusions: Epicardial CC use was associated with more periprocedural pericardial effusion than septal CC use. No statistically significant differences in technical success or long-term MACE were detected; these findings do not establish equivalence and are subject to anatomical selection and residual confounding.

22 September 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ZHZehan Huang
Zehan Huang
QWQiheng Wan
Qiheng Wan
YZYaoJun Zhang
YaoJun Zhang
FHFeiHuang Han
FeiHuang Han
DMDunLiang Ma
DunLiang Ma
BZBin Zhang
Bin Zhang

Verified
Journal Article
Open access
PDF file
SWSong Wen
Song Wen
SWShupei Wu
Shupei Wu
HYHUANG Yu-qing
HUANG Yu-qing
DMDunliang Ma
Dunliang Ma
FWFeng Wang
Feng Wang
RCRenjie Chai
Renjie Chai
Background: The role of the Guidezilla guide extension catheter during retrograde chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains uncertain. We examined its associations with procedural success, reported complications, and subsequent clinical events. Methods: This retrospective single-centre study included 819 patients undergoing elective retrograde CTO PCI between January 2011 and April 2023. Procedural associations were evaluated using logistic regression and propensity score matching. Long-term outcomes were evaluated using Kaplan–Meier analysis and Cox regression. Results: The Guidezilla guide extension catheter was used in 281 patients (34.3%). Retrograde technical success was 95.0% versus 87.0%, and final recanalisation success was 96.1% versus 88.3% (both p < 0.001). Corresponding adjusted odds ratios (ORs) were 3.80 (95% confidence interval [CI] 2.11–7.32) and 4.30 (95% CI 2.26–8.94; both p < 0.001). Associations persisted in 259 matched pairs (ORs 2.54, 95% CI 1.34–4.82, and 2.90, 95% CI 1.41–5.95; both p = 0.004). Reported in-hospital complications did not differ significantly, but rare events limited comparative safety assessment. In the fully adjusted Cox model, hazard ratios (HRs) were 0.99 (95% CI 0.48–2.04; p = 0.976) for cardiovascular events and 1.28 (95% CI 0.81–2.03; p = 0.295) for major adverse cardiovascular events. Conclusions: Guidezilla guide extension catheter use was associated with higher procedural success. These observational findings remain susceptible to selection bias and residual confounding, while limited event numbers preclude firm conclusions regarding comparative safety and long-term outcomes. Prospective confirmation is warranted.